BCG vaccination induces different cytokine profiles following infant BCG vaccination in the UK and Malawi

Journal of Infectious Diseases

Volumn 204, Issue 7, 2011, Pages 1075-1085

  Lalor, Maeve K ^a   Floyd, Sian ^a   Gorak Stolinska, Patricia ^a   Ben Smith, Anne ^a,b   Weir, Rosemary E ^a   Smith, Steven G ^a   Newport, Melanie J ^c   Blitz, Rose ^a   Mvula, Hazzie ^b   Branson, Keith ^a   McGrath, Nuala ^a   Crampin, Amelia C ^a,b   Fine, Paul E ^a   Dockrell, Hazel M ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b KARONGA PREVENTION STUDY   (Malawi)

^c UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; CD40 LIGAND; CHEMOKINE; CYTOKINE; EOTAXIN; FRACTALKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GROWTH FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 3; PLATELET DERIVED GROWTH FACTOR AA; RANTES; TUBERCULIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BCG VACCINATION; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; HUMAN; IMMUNE RESPONSE; INFANT; INNATE IMMUNITY; MALAWI; NEWBORN; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; SUPERNATANT; TH1 CELL; UNITED KINGDOM;

ADAPTIVE IMMUNITY; BCG VACCINE; BIOLOGICAL MARKERS; CELLS, CULTURED; CYTOKINES; GREAT BRITAIN; HUMANS; INFANT; INFANT, NEWBORN; MALAWI; PRINCIPAL COMPONENT ANALYSIS; TH1 CELLS; TIME FACTORS; TUBERCULIN; TUBERCULOSIS; VACCINATION;

EID: 80052395862     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir515     Document Type: Article

References (38)

1. Kaufmann S.H., Parida S.K. Tuberculosis in Africa: Learning from pathogenesis for biomarker identification. Cell Host Microbe 2008; 4:219-228
2. Fine P.E. Variation in protection by BCG: Implications of and for heterologous immunity. Lancet 1995; 346:1339-1345
3. Rodrigues L.C., Diwan V.K., Wheeler J.G. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: A meta-analysis. Int J Epidemiol 1993; 22:1154-1158 (Pubitemid 24025695)
4. Marchant A., Goetghebuer T., Ota M.O., et al. Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guerin vaccination. J Immunol 1999; 163:2249-2255 (Pubitemid 29382234)
5. Vekemans J., Amedei A., Ota M.O., et al. Neonatal bacillus Calmette-Guerin vaccination induces adult-like IFN-gamma production by CD4+ T lymphocytes. Eur J Immunol 2001; 31:1531-1535 (Pubitemid 32454701)
6. Finan C., Ota M.O., Marchant A., Newport M.J. Natural variation in immune responses to neonatal Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccination in a cohort of Gambian infants. PLoS One 2008; 3:e3485.
7. Soares A.P., Scriba T.J., Joseph S., et al. Bacillus Calmette-Guerin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J Immunol 2008; 180:3569-3577
8. Kagina B.M., Abel B., Scriba T.J., et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am J Respir Crit Care Med 2010; 182:1073-1079
9. Lalor M.K., Ben-Smith A., Gorak-Stolinska P., et al. Population differences in immune responses to bacille Calmette-Guerin vaccination in infancy. J Infect Dis 2009; 199:795-800.
10. Djoba Siawaya J.F., Roberts T., Babb C., et al. An evaluation of commercial fluorescent bead-based luminex cytokine assays. PLoS One 2008; 3:e2535.
11. Lalor M.K., Smith S.G., Floyd S., et al. Complex cytokine profiles induced by BCG vaccination in UK infants. Vaccine 2009; 28:1635-1641
12. Colditz G.A., Berkey C.S., Mosteller F., et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: Meta-analyses of the published literature. Pediatrics 1995; 96:29-35.
13. Jacobs M., Brown N., Allie N., Ryffel B. Fatal Mycobacterium bovis BCG infection in TNF-LT-alpha-deficient mice. Clin Immunol 2000; 94:192-199 (Pubitemid 30141747)
14. Cooper A.M., Magram J., Ferrante J., Orme I.M. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J Exp Med 1997; 186:39-45. (Pubitemid 27304845)
15. Algood H.M., Lin P.L., Flynn J.L. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 2005; 41(suppl 3):S189-S193 (Pubitemid 41022089)
16. Hussain R., Kaleem A., Shahid F., et al. Cytokine profiles using wholeblood assays can discriminate between tuberculosis patients and healthy endemic controls in a BCG-vaccinated population. J Immunol Methods 2002; 264:95-108. (Pubitemid 34615896)
17. Djoba Siawaya J.F., Beyers N., Van Helden P., Walzl G. Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosis. Clin Exp Immunol 2009; 156:66-77.
18. Azzurri A., Sow O.Y., Amedei A., et al. IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect 2005; 7:1-8. (Pubitemid 40431338)
19. Rook G.A., Dheda K., Zumla A. Immune systems in developed and developing countries; implications for the design of vaccines that will work where BCG does not. Tuberculosis (Edinb) 2006; 86:152-162
20. + T cells and protective memory against tuberculosis. Tuberculosis (Edinb) 2007; 87:465-473
21. Romano M., D'Souza S., Adnet P.Y., et al. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. Vaccine 2006; 24:3353-3364
22. Veldhoen M., Uyttenhove C., Van Snick J., et al. Transforming growth factor-beta "reprograms" the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 2008; 9:1341-1346
23. Burl S., Adetifa U.J., Cox M., et al. Delaying bacillus Calmette-Guerin vaccination from birth to 4 1/2 months of age reduces postvaccination Th1 and IL-17 responses but leads to comparable mycobacterial responses at 9 months of age. J Immunol 2010; 185:2620-2628
24. Rubin L.A., Jay G., Nelson D.L. The released interleukin 2 receptor binds interleukin 2 efficiently. J Immunol 1986; 137:3841-3844 (Pubitemid 17215312)
25. Rook G.A. Th2 cytokines in susceptibility to tuberculosis. Curr Mol Med 2007; 7:327-337 (Pubitemid 46767790)
26. Wu B., Huang C., Kato-Maeda M., et al. IL-9 is associated with an impaired Th1 immune response in patients with tuberculosis. Clin Immunol 2008; 126:202-210
27. Martinez F.O., Helming L., Gordon S. Alternative activation of macrophages: An immunologic functional perspective. Annu Rev Immunol 2009; 27:451-483
28. Mariotti S., Teloni R., Iona E., et al. Mycobacterium tuberculosis diverts alpha interferon-induced monocyte differentiation from dendritic cells into immunoprivileged macrophage-like host cells. Infect Immun 2004; 72:4385-4392 (Pubitemid 38989294)
29. Marchant A., Amedei A., Azzurri A., et al. Polarization of PPD-specific T-cell response of patients with tuberculosis from Th0 to Th1 profile after successful antimycobacterial therapy or in vitro conditioning with interferon-alpha or interleukin-12. Am J Respir Cell Mol Biol 2001; 24:187-194 (Pubitemid 32152081)
30. Chen X., O'Donnell M.A., Luo Y. Dose-dependent synergy of Th1-stimulating cytokines on bacille Calmette-Guerin-induced interferongamma production by human mononuclear cells. Clin Exp Immunol 2007; 149:178-185 (Pubitemid 46897114)
31. Ben-Smith A., Gorak-Stolinska P., Floyd S., et al. Differences between naive and memory T cell phenotype in Malawian and UK adolescents: A role for cytomegalovirus? BMC Infect Dis 2008; 8:139.
32. Reed J.R., Vukmanovic-Stejic M., Fletcher J.M., et al. Telomere erosion in memory T cells induced by telomerase inhibition at the site of antigenic challenge in vivo. J Exp Med 2004; 199:1433-1443 (Pubitemid 38685734)
33. Akbar A.N., Vukmanovic-Stejic M. Telomerase in T lymphocytes: Use it and lose it? J Immunol 2007; 178:6689-6694
34. Melchionda F., Fry T.J., Milliron M.J., McKirdy M.A., Tagaya Y., Mackall C.L. Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. J Clin Invest 2005; 115:1177-1187 (Pubitemid 40629036)
35. Triccas J.A., Shklovskaya E., Spratt J., et al. Effects of DNA- and Mycobacterium bovis BCG-based delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis. Infect Immun 2007; 75: 5368-5375 (Pubitemid 350033625)
36. Hanekom W.A. The immune response to BCG vaccination of newborns. Ann N Y Acad Sci 2005; 1062:69-78.
37. Jahn A., Floyd S., Mwinuka V., et al. Ascertainment of childhood vaccination histories in northern Malawi. Trop Med Int Health 2008; 13: 129-138 (Pubitemid 351271398)
38. Smith S.G., Lalor M.K., Gorak-Stolinska P., et al. Mycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining. BMC Immunol 2010; 11:35.